CL2011000832A1 - Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades. - Google Patents

Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.

Info

Publication number
CL2011000832A1
CL2011000832A1 CL2011000832A CL2011000832A CL2011000832A1 CL 2011000832 A1 CL2011000832 A1 CL 2011000832A1 CL 2011000832 A CL2011000832 A CL 2011000832A CL 2011000832 A CL2011000832 A CL 2011000832A CL 2011000832 A1 CL2011000832 A1 CL 2011000832A1
Authority
CL
Chile
Prior art keywords
thieno
adenosine
diseases
amine
pharmaceutical composition
Prior art date
Application number
CL2011000832A
Other languages
English (en)
Inventor
J Kent Barbay
Devraj Chakravarty
Brian Christopher Shook
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2011000832A1 publication Critical patent/CL2011000832A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composición farmacéutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
CL2011000832A 2008-10-13 2011-04-13 Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades. CL2011000832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10478108P 2008-10-13 2008-10-13
US12/479,158 US20100093702A1 (en) 2008-10-13 2009-06-05 METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
CL2011000832A1 true CL2011000832A1 (es) 2011-07-15

Family

ID=42099433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000832A CL2011000832A1 (es) 2008-10-13 2011-04-13 Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.

Country Status (17)

Country Link
US (1) US20100093702A1 (es)
EP (1) EP2350092A1 (es)
JP (1) JP2012505264A (es)
KR (1) KR20110071109A (es)
CN (1) CN102245614A (es)
AU (1) AU2009303694A1 (es)
BR (1) BRPI0920217A2 (es)
CA (1) CA2740406A1 (es)
CL (1) CL2011000832A1 (es)
CO (1) CO6321169A2 (es)
EA (1) EA201170563A1 (es)
EC (1) ECSP11010977A (es)
IL (1) IL212173A0 (es)
MX (1) MX2011003962A (es)
PE (1) PE20110423A1 (es)
WO (1) WO2010045006A1 (es)
ZA (1) ZA201103489B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301950B2 (en) 2009-08-21 2016-04-05 The Trustees Of The University Of Pennsylvania Adamantane analogs
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
US9884832B2 (en) * 2011-12-06 2018-02-06 The Trustees Of The University Of Pennsylvania Inhibitors targeting drug-resistant influenza A
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CN110573518A (zh) 2017-01-26 2019-12-13 尤拉·S·赞特里佐斯 被取代的双环嘧啶基化合物及其组合物和用途
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CR20250520A (es) * 2023-05-09 2025-12-19 Amgen Inc Alcoholes y éteres bicíclicos 5,6-condensados y 6,6-condensados y composiciones para su uso como moduladores de la 15-prostaglandina deshidrogenasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959432A (en) * 1996-02-16 1999-09-28 Asulab S.A. Device for charging a battery using a photovoltaic cell, and timepiece comprising same
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
SI1283839T1 (es) * 2000-05-26 2005-08-31 Schering Corp
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Also Published As

Publication number Publication date
BRPI0920217A2 (pt) 2015-12-22
KR20110071109A (ko) 2011-06-28
ECSP11010977A (es) 2011-05-31
EP2350092A1 (en) 2011-08-03
WO2010045006A1 (en) 2010-04-22
JP2012505264A (ja) 2012-03-01
IL212173A0 (en) 2011-06-30
CO6321169A2 (es) 2011-09-20
CN102245614A (zh) 2011-11-16
CA2740406A1 (en) 2010-04-22
ZA201103489B (en) 2012-11-28
PE20110423A1 (es) 2011-07-08
MX2011003962A (es) 2011-05-03
EA201170563A1 (ru) 2011-10-31
US20100093702A1 (en) 2010-04-15
AU2009303694A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
CY2024019I1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)- 5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
DOP2011000171A (es) Compuestos organico
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
ECSP12011855A (es) COMPUESTOS DE pIrrolo[2,3-d]pIrimidinA
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
DOP2011000175A (es) Compuestos organicos
CO6390082A2 (es) Compuestos organicos
SV2006002175A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
HK1213018A1 (zh) 橋接雙環核苷
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
EP2139332A4 (en) SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
CR9568A (es) DERIVADOS DE PIRIDO[2,3-d]PIRIMIDINA, SU PREPARACION, SU APLICACION EN TERAPEUTICA
DE602007012313D1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate
GT200600081A (es) Derivados de acetilenno
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors